Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EpiCept initiates advanced cancer study
EPC2407 is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors include the frequently occurring cancers of the lung, gastrointestinal
EPC2407 is intended for the treatment of advanced cancer patients with solid tumors that are well vascularized. These tumors include the frequently occurring cancers of the lung, gastrointestinal
The proof of concept trial is designed to evaluate the analgesic effects of TC-2696 following dental surgery. Targacept has previously conducted a phase I single ascending dose trial
The study was designed to assess the safety and efficacy of a 28-day treatment course with aztreonam lysine, as well as its ability to maintain or improve clinical
Final approval is expected upon expiry of patent protection for the brand product on June 12, 2007. Upon final approval, Lupin’s trandolapril tablets will be the AB-rated generic
The decision was made by the European Patent Office, after Ratiopharm appealed against the patent, which protected companies making cheaper generic copies of Nexium. Nexium is used in
This trial is expected to begin following completion of the current phase I/II trial. To date, Advaxis has completed enrollment and dosing of the first two of four
The phase Ia trial will assess safety, tolerability, pharmacokinetics and food affect in a single ascending dose study. InterMune expects to dose the first patient with ITMN-191 sometime
A priority designation accelerates review of the drug and is often given to a drug that, if approved, would be a significant improvement compared with existing treatments. The
The trial is being conducted in seven centers throughout Sweden and will focus on exploring the safety and tolerability of PBT2. The phase IIa study will also examine
The Mylan brand of finasteride, a generic version of Merck’s Proscar, is approved for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate to